These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 28339594

  • 1. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.
    Sykes JE, Hodge G, Singapuri A, Yang ML, Gelli A, Thompson GR.
    Med Mycol; 2017 Jun 01; 55(4):396-401. PubMed ID: 28339594
    [Abstract] [Full Text] [Related]

  • 2. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F, Hare Jensen R, Meis JF, Arendrup MC.
    Mycoses; 2016 Sep 01; 59(9):576-84. PubMed ID: 27061834
    [Abstract] [Full Text] [Related]

  • 3. Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.
    Yang ML, Uhrig J, Vu K, Singapuri A, Dennis M, Gelli A, Thompson GR.
    Antimicrob Agents Chemother; 2015 Dec 07; 60(3):1202-7. PubMed ID: 26643330
    [Abstract] [Full Text] [Related]

  • 4. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J.
    Antimicrob Agents Chemother; 2012 Nov 07; 56(11):5898-906. PubMed ID: 22948877
    [Abstract] [Full Text] [Related]

  • 5. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
    Moreira IMB, Cortez ACA, de Souza ÉS, Pinheiro SB, de Souza Oliveira JG, Sadahiro A, Cruz KS, Matsuura ABJ, Melhem MSC, Frickmann H, de Souza JVB.
    Med Mycol; 2022 Mar 03; 60(3):. PubMed ID: 35084497
    [Abstract] [Full Text] [Related]

  • 6. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA, Arthur I, Merritt A, Leung M.
    Med Mycol; 2019 Nov 01; 57(8):1004-1010. PubMed ID: 30649538
    [Abstract] [Full Text] [Related]

  • 7. Heteroresistance of Cryptococcus gattii to fluconazole.
    Varma A, Kwon-Chung KJ.
    Antimicrob Agents Chemother; 2010 Jun 01; 54(6):2303-11. PubMed ID: 20385871
    [Abstract] [Full Text] [Related]

  • 8. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS, Nawange SR, Singh SM, Yadu R, Tiwari A, Gumasta R, Kavishwar A.
    Braz J Microbiol; 2015 Jun 01; 46(4):1125-33. PubMed ID: 26691471
    [Abstract] [Full Text] [Related]

  • 9. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
    Basso LR, Gast CE, Bruzual I, Wong B.
    J Antimicrob Chemother; 2015 May 01; 70(5):1396-407. PubMed ID: 25630649
    [Abstract] [Full Text] [Related]

  • 10. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R, Fuchs V, Graf B, Hamprecht A, Hogardt M, Sedlacek L, Schwarz R, Idelevich EA, Becker SL, Held J, Küpper-Tetzel CP, McCormick-Smith I, Heckmann D, Gerkrath J, Han CO, Wilmes D, Rickerts V.
    Int J Med Microbiol; 2019 Sep 01; 309(6):151336. PubMed ID: 31444102
    [Abstract] [Full Text] [Related]

  • 11. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains.
    Silva DC, Martins MA, Szeszs MW, Bonfietti LX, Matos D, Melhem MS.
    Diagn Microbiol Infect Dis; 2012 Apr 01; 72(4):332-9. PubMed ID: 22341512
    [Abstract] [Full Text] [Related]

  • 12. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
    Gast CE, Basso LR, Bruzual I, Wong B.
    Antimicrob Agents Chemother; 2013 Nov 01; 57(11):5478-85. PubMed ID: 23979758
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H, Fukuda Y, Mitsuyama J, Tashiro M, Tanaka A, Takazono T, Saijo T, Yamamoto K, Nakamura S, Imamura Y, Miyazaki T, Kakeya H, Yamamoto Y, Yanagihara K, Mukae H, Kohno S, Izumikawa K.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1709-1713. PubMed ID: 28201509
    [Abstract] [Full Text] [Related]

  • 14. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the Cryptococcus neoformans Complex in Jiangxi Province, South Central China.
    Yang C, Bian Z, Blechert O, Deng F, Chen H, Li Y, Yang Y, Chen M, Zhan P.
    Front Cell Infect Microbiol; 2021 Jun 01; 11():723251. PubMed ID: 34790585
    [Abstract] [Full Text] [Related]

  • 15. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
    Grizante Barião PH, Tonani L, Cocio TA, Martinez R, Nascimento É, von Zeska Kress MR.
    Mycoses; 2020 Dec 01; 63(12):1341-1351. PubMed ID: 32869413
    [Abstract] [Full Text] [Related]

  • 16. Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.
    Singer LM, Meyer W, Firacative C, Thompson GR, Samitz E, Sykes JE.
    J Clin Microbiol; 2014 Jun 01; 52(6):2061-70. PubMed ID: 24696030
    [Abstract] [Full Text] [Related]

  • 17. Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex.
    Bandalizadeh Z, Shokohi T, Badali H, Abastabar M, Babamahmoudi F, Davoodi L, Mardani M, Javanian M, Cheraghmakani H, Sepidgar AA, Badiee P, Khodavaisy S, Afshari SAK, Ahmadikia K, Seyedmousavi S.
    J Med Microbiol; 2020 Jan 01; 69(1):72-81. PubMed ID: 31750814
    [Abstract] [Full Text] [Related]

  • 18. Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment.
    Chang M, Sionov E, Khanal Lamichhane A, Kwon-Chung KJ, Chang YC.
    Antimicrob Agents Chemother; 2018 Apr 01; 62(4):. PubMed ID: 29378705
    [Abstract] [Full Text] [Related]

  • 19. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
    Bastos RW, Carneiro HCS, Oliveira LVN, Rocha KM, Freitas GJC, Costa MC, Magalhães TFF, Carvalho VSD, Rocha CE, Ferreira GF, Paixão TA, Moyrand F, Janbon G, Santos DA.
    Antimicrob Agents Chemother; 2018 Jan 01; 62(1):. PubMed ID: 29109169
    [Abstract] [Full Text] [Related]

  • 20. Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.
    González GM, Casillas-Vega N, Garza-González E, Hernández-Bello R, Rivera G, Rodríguez JA, Bocanegra-Garcia V.
    Folia Microbiol (Praha); 2016 Jan 01; 61(1):51-6. PubMed ID: 26109075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.